Abstract
Background and objectives: Prenatal care provides pregnant women with regular opportunities to meet healthcare professionals while not being ill. Nothing similar currently takes place for the second parent. In the PARTAGE project, a prenatal consultation dedicated to future fathers, focused on preserving and improving their own health, has been tested and proven highly acceptable. In this work we analyse the results of this consultation on fathers' health and to whom it was most useful. Design: PARTAGE was a monocentric interventional study without control arm.Setting: A large public maternity ward in a northeastern suburb of Paris, an area where immigration prevails.Participants: Among 2516 eligible future fathers with effective contact, 1333 were included; fourteen additional sought the consultation directly. Intervention: PARTAGE ran from January 2021 to April 2022 (15 months). A physician or a midwife held a medical interview, extended by a physical examination if symptoms were reported, prescribed immediate biological tests, administered vaccination catch-up when necessary, and offered healthcare and social referral depending on participants' needs. Outcome measures: In this work, we describe the consultation's effects among participant future fathers: HIV lifetime screening rate, HIV prenatal screening rate and test acceptance among delayed participants; Diphtheria-Tetanus-Pertussis-Poliomyelitis (DTaP-IPV) and Measles-Mumps-Rubella (MMR) vaccination coverage and on-site catch-up rates; diagnosis rate for any medical pathology, including reintegration into care of a lost-to-follow-up pathology; medical and social reference rates.Results: Paternal prenatal consultations resulted in prevention, diagnosis and linkage into care: 37% of participants had never been tested for HIV; 96% had not been tested during or immediately prior to the current pregnancy, of whom 98% accepted HIV screening; 72% were out-of-date for DTaP-IPV or MMR vaccinations, of whom 60% received an on-site catch-up. In addition, 18% had at least one pathology diagnosed or brought back into care; 17% were referred to healthcare professionals and 11% to social workers. Whatever the outcome considered, paternal prenatal consultation benefited socially disadvantaged participants the most: in multivariate analysis, being born in Sub Saharan Africa rather than in France and having no health insurance coverage rather than a complete one were associated with a medical diagnosis (OR 2.67 [1.80-3.98] and OR 2.58 [1.63-4.09], respectively) and with a referral to a healthcare professional (OR 2.67 [1.80-3.98] and OR 3.63 [2.27-5.80], respectively). Conclusion: Paternal prenatal consultations led to the diagnosis of undetected illnesses and to the resumption of care for pathologies that had already been diagnosed but were previously lost to follow-up, especially in the most socially disadvantaged future fathers, who were also enabled to meet social workers when necessary. Paternal prenatal consultations were also broadly useful for catching-up on HIV screening and vaccinations in all expectant fathers. Addressing men's health during their partner's pregnancy could help reduce gender and social inequalities in health.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05085717
Funding Statement
The PARTAGE study was financed by the French Agency for research on AIDS, viral hepatitis, tuberculosis and emerging infectious diseases (ANRS-MIE) (research team's salaries) and by the French Society against AIDS (SFLS - implementation and evaluation of a Saturday consultation outside hospital walls). Montreuil's hospital also received a donation from Gilead Sciences, Inc. to develop PARTAGE's communication and IT tools.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The French Data Protection Authority (CNIL, registration number 921135) and the French Personal Data Protection Committee (Comite de Protection des Personnes, registration number 21.01.19.44753) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
